Allografts in joint reconstruction: ESSKA making a difference

Tim Spalding; Peter Verdonk; Laura de Girolamo; Romain Seil; David Dejour

doi:10.1007/s00167-019-05514-2

Allografts in joint reconstruction: ESSKA making a difference

Tim Spalding^*, Peter Verdonk, Laura de Girolamo, Romain Seil, David Dejour

^*Corresponding author for this work

Research output: Contribution to journal › Editorial

3 Citations (Scopus)

Original language	English
Pages (from-to)	1701-1703
Number of pages	3
Journal	Knee Surgery, Sports Traumatology, Arthroscopy
Volume	27
Issue number	6
DOIs	https://doi.org/10.1007/s00167-019-05514-2
Publication status	Published - 1 Jun 2019
Externally published	Yes

Access to Document

10.1007/s00167-019-05514-2

Cite this

@article{70da3bda7e8a4a89a96775073e09b7af,

title = "Allografts in joint reconstruction: ESSKA making a difference",

author = "Tim Spalding and Peter Verdonk and \{de Girolamo\}, Laura and Romain Seil and David Dejour",

note = "Funding Information: Allograft technologies might be more expensive, and their sustainability needs to be justified in the world of rationing healthcare. Each country in Europe and worldwide will have their own level of value for a treatment but the cornerstone for any approval to use such clinically valuable treatments is accurate cost-effectiveness information, and this is the basis of the initiative. The cost-effectiveness Health Technology Appraisal (HTA) was funded through the ESSKA Foundation.",

year = "2019",

month = jun,

day = "1",

doi = "10.1007/s00167-019-05514-2",

language = "English",

volume = "27",

pages = "1701--1703",

journal = "Knee Surgery, Sports Traumatology, Arthroscopy",

issn = "0942-2056",

publisher = "John Wiley and Sons Inc",

number = "6",

}

TY - JOUR

T1 - Allografts in joint reconstruction

T2 - ESSKA making a difference

AU - Spalding, Tim

AU - Verdonk, Peter

AU - de Girolamo, Laura

AU - Seil, Romain

AU - Dejour, David

N1 - Funding Information: Allograft technologies might be more expensive, and their sustainability needs to be justified in the world of rationing healthcare. Each country in Europe and worldwide will have their own level of value for a treatment but the cornerstone for any approval to use such clinically valuable treatments is accurate cost-effectiveness information, and this is the basis of the initiative. The cost-effectiveness Health Technology Appraisal (HTA) was funded through the ESSKA Foundation.

PY - 2019/6/1

Y1 - 2019/6/1

UR - https://www.scopus.com/pages/publications/85065657922

U2 - 10.1007/s00167-019-05514-2

DO - 10.1007/s00167-019-05514-2

M3 - Editorial

C2 - 31076824

AN - SCOPUS:85065657922

SN - 0942-2056

VL - 27

SP - 1701

EP - 1703

JO - Knee Surgery, Sports Traumatology, Arthroscopy

JF - Knee Surgery, Sports Traumatology, Arthroscopy

IS - 6

ER -

Allografts in joint reconstruction: ESSKA making a difference

Access to Document

Other files and links

Cite this